계명대학교 의학도서관 Repository

Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial

Metadata Downloads
Author(s)
Kyung Hee LeeBong Seog KimSang Cheul OhSam Yong KimSang Jae LeeJoung-Soon JangHo Yeong LimIn Gyu HwangHong Suk SongNaeChoon YooSoYoung YoonYeul Hong KimEunsik ParkJae Ho ByunMyung Ah LeeSuk Joong Oh
Keimyung Author(s)
Song, Hong Suk
Department
Dept. of Internal Medicine (내과학)
Journal Title
Cancer Chemotherapy and Pharmacology
Issued Date
2010
Volume
65
Issue
4
Abstract
Purpose : Chemotherapy represents a palliative treatment, with poor response rates and a median survival of less than 6 months in patients with biliary tract cancers (BTCs). The aim of this study was to evaluate the efficacy and safety of the combination chemotherapy with gemcitabine and oxaliplatin (GEMOX) in patients with BTCs including gall bladder cancer.
Methods : We carried out a nationwide multicenter phase II study evaluated the efficacy and safety of GEMOX as first-line therapy in patients with advanced BTCs. Eligible patients with previously untreated locally advanced or metastatic BTCs received gemcitabine 1,000 mg/m2 (day 1 and 8) and oxaliplatin 100 mg/m2 (day 1), every 3 weeks.
Results : Fifty-three patients were evaluated, 60% had cholangiocarcinoma and the remaining 40% gall bladder cancer; the objective response rate was 18.9% (10/53 patients including 1 Complete response) [14.9%; 95% confidence interval (CI), 7.4–25.7%] in the treated population. Stable disease were observed in 27/53 (50.9%) patients, disease control rate was achieved in 69.8% of all patients. Median progression-free survival was 4.8 months (3.1–6.5, 95% CI) and median overall survival was 8.3 months (5.8–10.8, 95% CI). Grade 3/4 toxicities included neutropenia (33.9% of patients) and thrombocytopenia (7.6%).
Conclusions : The GEMOX regimen demonstrated a modest antitumor activity and is well tolerated in patients with advanced BTCs.
Keywords : Biliary tract cancers – Chemotherapy – Gemcitabine – Oxaliplatin
Keimyung Author(s)(Kor)
송홍석
Publisher
School of Medicine
Citation
Kyung Hee Lee et al. (2010). Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemotherapy and Pharmacology, 65(4), 641–647. doi: 10.1007/s00280-009-1069-7
Type
Article
ISSN
0344-5704
Source
http://lps3.link.springer.com.proxy.dsmc.or.kr/article/10.1007%2Fs00280-009-1069-7
DOI
10.1007/s00280-009-1069-7
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/35296
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.